EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Dupilumab efficacy by disease severity in pediatric type 2 asthma

Daniel J Jackson iD, Monika Gappa, Leonard B Bacharier, Antoine Deschildre iD, Kristie Ross, Changming Xia, Olivier Ledanois, Katherine Miller

Pediatric Allergy and Immunology · 2025-11 · 36 (11)

DOI: 10.1111/pai.70196 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Allergy and Immunology, online erschienen am 07.11.2025. Verfasst von Daniel J Jackson und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Anti-Asthmatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dupilumab demonstrated efficacy in children with asthma in phase 3 VOYAGE (NCT02948959) and open‐label extension EXCURSION (NCT03560466) studies. This post hoc analysis assessed dupilumab's long‐term efficacy by asthma severity at parent study baseline.

Methods

Children (6–11 years) with moderate‐to‐severe type 2 inflammatory asthma (PS baseline blood eosinophils ≥150 cells/μL or fractional exhaled nitric oxide ≥20 ppb) from placebo‐controlled VOYAGE who enrolled in EXCURSION received dupilumab every 2 weeks for an additional 52 weeks. We assessed annualized severe exacerbation rates, change in pre‐bronchodilator percent predicted forced expiratory volume in 1 second (FEV 1 ) and FEV 1 z ‐score, and Interviewer‐Administered 7‐item Asthma Control Questionnaire (ACQ‐7‐IA) score in subgroups with moderate (medium‐dose inhaled corticosteroid (ICS), pre‐bronchodilator percent predicted FEV 1 ≥ 80%) and severe (high‐dose ICS, pre‐bronchodilator percent predicted FEV 1 < 80%) asthma at parent study baseline.

Results

Among 179 children (104 with moderate, 75 with severe asthma), dupilumab compared to placebo reduced unadjusted annualized severe exacerbation rates during VOYAGE in children with moderate (0.22 vs. 0.37) and severe (0.41 vs. 1.07) asthma, with sustained reductions in EXCURSION (moderate: 0.07 and 0.07; severe: 0.24 and 0.19). At VOYAGE Week 52, the change from the parent study baseline in pre‐bronchodilator percent predicted FEV 1 was 8.6 versus 2.1 percentage points with dupilumab and placebo in children with moderate asthma, and 16.7 versus 9.8 percentage points in children with severe asthma. Improvements in the change from the parent study baseline in pre‐bronchodilator FEV 1 z ‐scores and ACQ‐7‐IA scores were also observed with dupilumab treatment in both subgroups.

Conclusion

Long‐term dupilumab treatment reduced exacerbation rates and improved lung function and asthma control in children with type 2 asthma irrespective of disease severity, with numerically greater improvements in children with severe asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAsthmaAnti-Asthmatic AgentsHumansChildMaleFemaleSeverity of Illness IndexTreatment OutcomeDouble-Blind MethodForced Expiratory VolumeEosinophils

Stichwörter der Autor:innen

asthmaclinical trialdisease exacerbationdupilumablung volumespatient‐reported outcome

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic Agents

Autor:innen und Institutionen

  • University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Children's Hospital, Evangelisches Krankenhaus Düsseldorf, Düsseldorf, Germany.
  • Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Pediatric Pulmonology and Allergy Department, Jeanne de Flandre Hospital, CHU Lille, University of Lille, Lille, France.
  • UH Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA.
  • Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.

ORCID-Profile: Daniel J Jackson, Antoine Deschildre

Förderung

  • Sanofi
  • Regeneron Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals

Zitieren

APA

Jackson, D. J., Gappa, M., Bacharier, L. B., Deschildre, A., Ross, K., Xia, C., Ledanois, O., & Miller, K. (2025). Dupilumab efficacy by disease severity in pediatric type 2 asthma. Pediatric Allergy and Immunology, 36(11). https://doi.org/10.1111/pai.70196

Vancouver

Jackson DJ, Gappa M, Bacharier LB, Deschildre A, Ross K, Xia C, et al. Dupilumab efficacy by disease severity in pediatric type 2 asthma. Pediatric Allergy and Immunology. 2025;36(11). doi:10.1111/pai.70196

BibTeX
@article{Jackson2025,
  author = {Jackson, Daniel J and Gappa, Monika and Bacharier, Leonard B and Deschildre, Antoine and Ross, Kristie and Xia, Changming and Ledanois, Olivier and Miller, Katherine},
  title = {Dupilumab efficacy by disease severity in pediatric type 2 asthma},
  journal = {Pediatric Allergy and Immunology},
  year = {2025},
  volume = {36},
  number = {11},
  doi = {10.1111/pai.70196}
}
Kostenlos starten →